Enhancing Early-Stage Cancer Treatment: Overcom...

By HEOR Staff Writer

February 10, 2026

Unlocking Early-Stage Cancer Treatment Gains Early-stage cancer treatment offers significant clinical, humanistic, and economic advantages through timely detection and intervention, yet f...
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
NHS Cost-Effectiveness Thresholds Boost Drug Approvals and Innovation
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Paving the Way for Digital Health Technologies: NICE’s Bold New Strateg...
NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Su...
NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...